A General Approach Towards Triazole-Linked Adenosine Diphosphate Ribosylated Peptides and Proteins by Liu, Q. et al.
German Edition: DOI: 10.1002/ange.201710527Protein Modification
International Edition: DOI: 10.1002/anie.201710527
AGeneral Approach Towards Triazole-Linked Adenosine
Diphosphate Ribosylated Peptides and Proteins
Qiang Liu, Hans A. V. Kistemaker, Sagar Bhogaraju, Ivan Dikic, Herman S. Overkleeft,
Gijsbert A. van der Marel, Huib Ovaa, Gerbrand J. van der Heden van Noort,* and
Dmitri V. Filippov*
Abstract: Current methods to prepare adenosine diphosphate
ribosylated (ADPr) peptides are not generally applicable due
to the labile nature of this post-translational modification and
its incompatibility with strong acidic conditions used in
standard solid-phase peptide synthesis. A general strategy is
presented to prepare ADPr peptide analogues based on
a copper-catalyzed click reaction between an azide-modified
peptide and an alkyne-modified ADPr counterpart. The scope
of this approach was expanded to proteins by preparing two
ubiquitin ADPr analogues carrying the biological relevant a-
glycosidic linkage. Biochemical validation using Legionella
effector enzyme SdeA shows that clicked ubiquitin ADPr is
well-tolerated and highlights the potential of this strategy to
prepare ADPr proteins.
Regulation of protein activity is controlled by post-transla-
tional modifications (PTMs) that are installed on specific
side-chain functionalities of amino acids in the involved
protein. Simple PTMs, such as acetylation, methylation, and
phosphorylation, have been subject of a large amount of
studies, and the focus of PTM research is shifting to more
complex PTMs. One of these PTMs is called adenosine
diphosphate ribose (ADPr), a modification in which a specific
nucleophilic side chain in the target protein displaces b-
oriented nicotinamide from NAD+ under the agency of an
ADPr-transferase (ART) resulting in an a-oriented glycosidic
linkage to the protein.[1] Mono-ADP-ribosylation is not only
a PTM effected by bacterial toxins and the starting point for
poly-ADP-ribosylation but also a regulatory modification in
its own right. Mono-ADP-ribosylation is reported to take
place on a variety of amino acid side chains, including arginine
(Figure 1), glutamic acid, aspartic acid, asparagine, and
cysteine, but recently it was pointed out that serine might
be the main point of attachment for ADP-ribosylation.[2]
Research in the field of protein ADP-ribosylation benefits
greatly from ADP-ribosylated molecular tools. One way to
obtain such tools in sufficient quantities is through chemical
synthesis. Methods towards naturally occurring mono-ADP-
ribosylated oligopeptides, ADPr oligomers, and NAD+-ana-
logues have been reported and employed in studying ADP-
ribosyl hydrolase affinity,[3] inhibition of ADP-ribosylating
toxins, finding substrate proteins for poly ADPr poly-
merases,[4] and determining the structure of poly ADP-
ribose glycohydrolases.[5] Such ADPr peptides and related
substances are valuable for the interrogation of the complex
biology that underlies this PTM.[6] In the chemical synthesis of
peptides and proteins, most commonly an acidic step to
remove protective groups is employed. Such conditions,
however, may cause either epimerization at the anomeric
center of ribose or complete loss of the ADPr-moiety. Mild
alkaline conditions, carry the risk of degradation of the b-
substituted amino acids and are clearly incompatible with the
esters of ADP-ribosylated Glu and ADP-ribosylated Asp.
The reported syntheses of ADPr amino acids and peptides so
Figure 1. Structure of a-linked ADPr arginine and ADPr triazole ana-
logue linkages.
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far have been carefully tuned to minimize those risks and
incorporation of ADPr amino acids asks for a modified
protective group strategy in most cases.[6a,7] To prevent the
need for highly specialized methods to prepare these amino
acid-ribose conjugates we propose a general strategy that
would allow a post-synthetic introduction of the ADPrmoiety
to a peptide or protein of interest.
We selected the ADPr triazole analogues as a relevant
replacement for ADPr amino acids in peptides (Figure 1).
Oligopeptides with an azide incorporated can be obtained by
standard solid phase peptide synthesis (SPPS) using an azido–
alanine or azido–homoalanine building block at the site of the
modification. After conventional synthesis and a copper-
catalyzed azide–alkyne cycloaddition (CuAAC) of the
obtained azido functionalized oligopeptide with a suitable
propargylated ADPr building block (ADPr-pr, 7 in Scheme 1)
results in the installation of the ADPr triazole functionality.
The synthesis of ADPr-pr 7 starts with the condensation of
propargyl alcohol with imidate ribose donor 1[7a] (Scheme 1)
to yield an anomeric mixture (a :b, 71:29). In contrast to two
previously reported syntheses that show the preparation of
either b-O-alkyne or b-azide containing ADPr analogues, we
were able to isolate the biologically relevant a-anomer.[5,8]
Protective-group exchange allows alkaline deprotection in
the final stage of the synthesis instead of acid treatment,
preventing possible degradation of the ADPr-pr moiety.
Phosphitylation of the primary alcohol and subsequent
oxidation furnishes crucial phosphotriester intermediate 4.
Removal of the tBu groups set the stage for the installation of
the pyrophosphate moiety using our previously reported
procedure.[9] Reaction of phosphomonoester 5 with suitably
protected adenosine phosphoramidite 6[10] using dicyanoimi-
dazole (DCI) as activator and oxidation of the intermediate
PIII-PV species was followed by a two-step alkaline depro-
tection procedure. Purification using size exclusion chroma-
tography gave access to ADPr-pr 7 in a quantity of 100 mg.
Formation of the pyrophosphate and subsequent deprotec-
tion proceeded in an overall isolated yield of 65%, which
compares favorably to other approaches.[6a,8, 11]
To assess the viability of ADPr-pr building block 7 in the
projected cycloaddition, we prepared three peptides derived
from mono-ADP-ribosylated proteins; namely Histone H2B
(2–14) (see Scheme 2, compound 8), RhoA (36–46)
(Scheme 2, compound 9) and human neutrophil defensin 1;
HNP1 (75–81) (see Scheme 2, compound 10). In the selected
peptides, we substituted Gln3, Asn50, and Arg78, respec-
tively, for b-azidoalanine to allow conjugation by copper-
catalyzed cycloaddition. After completion of the SPPS, the
immobilized oligopeptides were treated with a cleavage
mixture consisting of 90.5% trifluoroacetic acid (TFA), 5%
water, 2.5% phenol and 2% triisopropylsilane to globally
remove the protective groups and cleave the peptide from the
resin. RP-HPLC purification yielded target peptides 8–10 that
were used in the CuAAC reaction with ADPr-pr 7 in 20 mm
tris(hydroxymethyl)aminomethane/150 mm NaCl buffer at
pH 7.6 under the agency of 10 mm CuSO4, 60 mm sodium
ascorbate, and 10 mm tris triazole ligand.[12] Since these
peptides and ADPr-pr 7 dissolved readily in this buffer, the
click reaction proceeded efficiently and quickly (within
minutes to one hour), in contrast to a previous study.[8] To
mimic the length of the Arg-ADPr linkage more closely, we
prepared HNP1-peptide 11 in which the Arg was replaced not
with b-azidoalanine but with azido-homoalanine. Again
CuAAC to ADPr-pr proceeded uneventfully, yielding 15.
Having established an efficient procedure to prepare
ADPr oligopeptides, we were eager to see whether our
method could be expanded in preparation of ADPr proteins.
Ubiquitin (Ub), a 76 amino acid residue long post-transla-
tional modifier itself, has recently been found to be modified
with ADPr on different positions. This cross-talk between
ADP-ribosylation and ubiquitination is reported to have
a regulatory effect on the DNA repair mechanism, where low
levels of NAD lead to ubiquitination of histone protein H4,
but high levels of NAD lead to ADP-ribosylation of Gly76;
the C-terminus of Ub.[13]Other studies show that Arg42 of Ub
is ADP-ribosylated by a family of effector proteins originat-
ing from Legionella pneumophila, the pathogen causing
LegionnairesQ disease.[14] These SidE effectors are the first
reported class of enzymes that are able to ubiquitinate target
proteins independent of the normally employed enzymatic
cascade of E1, E2, and E3 enzymes, utilizing Ub-ADPr as
crucial intermediate. Using their unique properties, SidE
Scheme 1. Synthesis of ADPr-propargyl 7.
Scheme 2. CuAAC reaction towards ADPr peptides.
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proteins can hijack the host cells Ub pool and use it to its own
advantage. In analogy to peptide 11, we prepared Ub mutant
16 in which Arg42 is replaced by azido-homoalanine using our
previously published linear SPPS approach.[15] Gly76 modi-
fied Ub 17 was prepared by first synthesizing Ub75 on trityl
resin followed by treatment with mild acid (20% hexafluor-
oisopropanol in dichloromethane). In this step the peptide
was liberated from the solid support while leaving all side-
chain protecting groups in place. Activation of the free C-
terminal carboxylic acid and coupling of 3-azido-1-propan-
amine followed by strong acid treatment and RP-HPLC
purification yielded azide modified Ub 17. Copper-catalyzed
click reaction with ADPr-pr building block 7 followed by
dialysis to remove traces of excess ADPr-pr and click reagents
followed by size exclusion chromatography gave easy access
to ADP-ribosylated ubiquitin analogues 18 and 19, respec-
tively (Scheme 3).
Of note is that this procedure does not require the use of
RP-HPLC purification after introduction of the ADPr
moiety. To assess whether the artificial triazole linkage is
tolerated and this method indeed results in useful ADPr-
protein analogues, we compared Ub-ADPr 18 to Arg42 Ub-
ADPr from natural sources (Ub-ADPr wt). Both Ub-ADPr
18 and Ub-ADPr wt were efficiently recognized by an ADPr-
antibody in western blot (Figure 2A, lower panel), a first
indication that the triazole analogue does not differ too far
from its natural counterpart. One of the properties of
Legionella effector SdeA is its auto-ubiquitination behavior,
an effect that is not fully understood so far, but is reported for
all four SidE family members. We compared the ability of
recombinant SdeA to use 18 in an auto-ubiquitination assay
and found indeed that SdeA is modified with Ub multiple
times (see Figure 2A,B). Although at a reduced rate com-
pared to Ub-ADPr wt, artificial 18 was processed by SdeA
and significant auto-ubiquitination takes place. A control
experiment using non-ADPribosylated wild type Ub shows
no auto-ubiquitination of SdeA (Figure 1; Supporting Infor-
mation). These results further confirm that Ub-ADPr con-
jugate 18 functions similar to Ub-ADPr wt.
In conclusion, we have presented the design and synthesis
of propargylated ADP-ribose building block (7) suitable to
take part in an efficient cycloaddition with oligopeptides and
proteins having an azide at a predetermined position. In this
way oligopeptides and proteins carrying an analogue of the
mono ADP-ribose post-translational modification are made
available. Four ADPr-oligopeptide conjugates derived from
known ADP-ribosylated proteins were prepared efficiently.
Furthermore, two analogues of ADPr ubiquitin, shown to
play a role in LegionnairesQ disease and DNA repair, were
prepared using the same copper-catalyzed chemistry. The
effectiveness of these reactions and subsequent purifications
provides an easy entry to this interesting class of post-
translational modified proteins. Triazole-containing Ub-
ADPr 18 was shown to be recognized in western blot and
accepted by SdeA in an auto-ubiquitination assay, indicating
that this method provides a useful platform for the biological
interrogation of ADPr biology.
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